strattera 10 mg trde kapsule
eli lilly farmacevtska druŽba, d.o.o. - atomoksetin - kapsula, trda - atomoksetin 10 mg / 1 kapsula - atomoksetin
strattera 18 mg trde kapsule
eli lilly farmacevtska druŽba, d.o.o. - atomoksetin - kapsula, trda - atomoksetin 18 mg / 1 kapsula - atomoksetin
strattera 25 mg trde kapsule
eli lilly farmacevtska druŽba, d.o.o. - atomoksetin - kapsula, trda - atomoksetin 25 mg / 1 kapsula - atomoksetin
strattera 40 mg trde kapsule
eli lilly farmacevtska druŽba, d.o.o. - atomoksetin - kapsula, trda - atomoksetin 40 mg / 1 kapsula - atomoksetin
strattera 60 mg trde kapsule
eli lilly farmacevtska druŽba, d.o.o. - atomoksetin - kapsula, trda - atomoksetin 60 mg / 1 kapsula - atomoksetin
strattera 4 mg/ml peroralna raztopina
eli lilly farmacevtska druŽba, d.o.o. - atomoksetin - peroralna raztopina - atomoksetin 4 mg / 1 ml - atomoksetin
cholestagel
cheplapharm arzneimittel gmbh - colesevelam (as hydrochloride) - hiperholesterolemija - sredstva za spreminjanje lipidov - cholestagel co-upravlja s 3-hydroxy-3-methyl-glutaryl-coenzyme-a (hmg-coa)-reduktazo zaviralci (statin) je navedena kot dodatno zdravljenje k dieti zagotoviti dodatek znižanje nizko-gostoto-lipoproteinov-raven holesterola v krvi (ldl-c) v odraslih bolnikih s primarno hiperholesterolemijo, ki ni ustrezno nadzorovana z statin sam. cholestagel kot monotherapy je označen kot adjunctive terapija za prehrane za zmanjšanje zvišan skupni holesterol in ldl-c pri odraslih bolnikih s primarno hypercholesterolaemia, v katero statin je neprimerno, ali ni dobro prenaša. cholestagel se lahko uporablja tudi v kombinaciji z ezetimibe, z ali brez statin, pri odraslih bolnikih s primarno hypercholesterolaemia, vključno z bolniki z družinsko hypercholesterolaemia (glej poglavje 5.
elonva
n.v. organon - korifolitropin alfa - reproductive techniques, assisted; ovulation induction; investigative techniques - spolni hormoni in zdravila genitalni sistem, - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program. elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human chorionic gonadotropin (hcg).
plegridy
biogen netherlands b.v. - peginterferon beta-1a - multiple skleroza - immunostimulants, - zdravljenje ponavljajoče se remitirne multiple skleroze pri odraslih bolnikih.
pegasys
pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 in 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. glede na odločitev, da začne zdravljenje v pediatrični bolniki glej točki 4. 2, 4. 4 in 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 in 5. za virus hepatitisa c (hcv) genotip določene dejavnosti, glej točki 4. 2 in 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. ko se odločate za začetek zdravljenja v otroštvu, je pomembno, da preuči zaviranja rasti povzročijo kombinacija terapije. reverzibilnost zaviranja rasti je negotova. odločitev za zdravljenje mora biti vložena na podlagi primera (glej poglavje 4.